IL18 and neoplasm: Thus, we postulate that the use of DCs able for simultaneous IL-12 and IL-18 production additionally stimulated with tumor antigens may generate a favorable impact on the activation of antitumor immune response, especially if these vaccine cells are administered repeatedly.